RVTY Q3 deep dive: AI demand and operational execution drive broad-based growth

What happened

Revvity reported Q3 2026 revenue of $709.6 million, up 7.4% year on year and above analysts’ estimates. Non-GAAP adjusted earnings per share were $1.37, also above estimates. The company raised its full-year revenue midpoint to $2.86 billion and adjusted earnings-per-share midpoint to $5.43.

Confirmed

Global impact / market context

Higher sales and a wider operating margin suggest Revvity converted stronger demand into improved operating performance this quarter. If that holds, it could support earnings and cash available for investment; the higher full-year earnings forecast signals management expects some of this progress to continue.

Analyst inference

The article attributes growth to improved demand from pharmaceutical and biotechnology customers, especially in Life Sciences, and strong execution in reagents and instruments. That ties results to customer research spending and Revvity’s ability to deliver products, rather than demand in a single product area.

Confirmed

What to watch

1. Check whether upcoming results show continued sales growth in Life Sciences and sustained demand from pharmaceutical and biotechnology customers, the demand sources management cited. Analyst inference
2. Compare reported full-year revenue and adjusted earnings per share with the raised midpoints of $2.86 billion and $5.43, respectively. Confirmed
3. Watch whether the operating margin, meaning the share of sales left after operating costs, remains above last year’s comparable-quarter level of 11.7%. Analyst inference

Evidence

• stockstory.org